Ferrer and IDIBELL develop EPICUP, the first epigenetic test for patients with cancer of unknown origin

Ferrer pharmaceutical company, with headquarters in Barcelona, ​​announced the launch of EPICUP, the first epigenetic diagnostic test based on the analysis of DNA methylation profiles and helps the oncologist to identify the primary tumor in patients with cancer of unknown origin (CUP).
The tool, fruit of public-private partnership between the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL) led by Manel Esteller, the IDIBELL Innovation Unit and the Area of ​​Innovation and Business development at FERRER, has a high degree of accuracy. So EPICUP becomes a good complement to the diagnostic methods currently used.

More information: http://www.idibell.cat/modul/news/en/816/ferrer-and-idibell-develop-epicup-the-first-epigenetic-test-for-patients-with-cancer-of-unknown-origin

  • 5th of June 2016
  • News

Comments are closed.